• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Dyne Therapeutics Inc.

    12/5/25 4:56:16 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001814189
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Dyne Therapeutics, Inc.
    SEC File Number
    001-39509
    Address of Issuer
    1560 TRAPELO ROAD
    WALTHAM
    MASSACHUSETTS
    02451
    Phone
    (781) 786-8230
    Name of Person for Whose Account the Securities are To Be Sold
    Kerr Douglas
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Stifel Nicolaus & Company Inc
    501 N Broadway
    St. Louis � MO � 63102
    88018231.0014282468712/05/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock12/04/2025Restricted Stock UnitsIssuerCheckbox not checked88012/05/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Doug Kerr
    1560 Trapelo Road
    Waltham � MA � 02451
    Common Stock09/05/202587311708.00
    Doug Kerr
    1560 Trapelo Road
    Waltham � MA � 02451
    Common Stock09/04/2025355247133.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/05/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Doug Kerr

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $DYN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    12/10/2025$40.00Perform → Outperform
    Oppenheimer
    10/10/2025Outperform → Perform
    Oppenheimer
    8/25/2025$35.00Outperform → Strong Buy
    Raymond James
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    More analyst ratings

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Cox John gifted 40,000 shares and bought $911,000 worth of shares (100,000 units at $9.11), increasing direct ownership by 42% to 202,179 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    7/15/25 5:11:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Cox John bought $1,057,216 worth of shares (32,000 units at $33.04) (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    9/4/24 5:42:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kersten Dirk bought $29,999,988 worth of shares (1,714,285 units at $17.50) (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    1/11/24 4:31:55 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Cox John sold $55,157 worth of shares (2,662 units at $20.72), decreasing direct ownership by 1% to 196,877 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    12/5/25 4:11:49 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kerr Douglas sold $18,234 worth of shares (880 units at $20.72), decreasing direct ownership by 1.00% to 87,510 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    12/5/25 4:09:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Friedl-Naderer Johanna sold $2,984 worth of shares (144 units at $20.72), decreasing direct ownership by 0.15% to 94,729 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    12/5/25 4:08:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    SEC Filings

    View All

    SEC Form 424B5 filed by Dyne Therapeutics Inc.

    424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

    12/10/25 4:31:58 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Dyne Therapeutics Inc.

    8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

    12/10/25 4:22:33 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Dyne Therapeutics Inc.

    424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

    12/8/25 4:19:09 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dyne Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Dyne Therapeutics from Perform to Outperform and set a new price target of $40.00

    12/10/25 8:10:44 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Dyne Therapeutics from Outperform to Perform

    10/10/25 8:28:51 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics upgraded by Raymond James with a new price target

    Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $35.00

    8/25/25 8:07:36 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

    WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $402.5 million, before deducting underwriting discounts and comm

    12/11/25 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

    WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $350.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about December 11, 2025, subject to customary c

    12/9/25 9:42:38 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces Proposed Public Offering of Common Stock

    WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. The proposed offering is subject t

    12/8/25 4:02:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Financials

    Live finance-specific insights

    View All

    Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

    - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose - - Functional improvement was observed across multiple clinical endpoints at 6 months in REC; lung function was preserved at 6 months - - New positive long-term results from DELIVER trial showed sustained functional improvement across all assessed endpoints through 24 months - - Continued favorable safety and tolerability profile - - Submission for U.S. Accelerated Approval on track for Q2 2026 - - Investor even

    12/8/25 6:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

    WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and WebcastThe webcast will be available on the Events & Presentations page of the Investors & Medi

    12/7/25 11:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

    - Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically

    6/17/25 7:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Leadership Updates

    Live Leadership Updates

    View All

    Dyne Therapeutics Appoints Brian Posner to its Board of Directors

    WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b

    10/2/25 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

    Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p

    7/16/25 7:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces CEO Transition

    - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles

    3/25/24 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 5:46:12 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:32:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:23:11 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care